Renovaro Inc.

DB:2Q5 Stock Report

Market Cap: €157.3m

Renovaro Management

Management criteria checks 1/4

Renovaro's CEO is David Weinstein, appointed in Oct 2024, has a tenure of less than a year. directly owns 0.16% of the company’s shares, worth €247.68K. The average tenure of the management team and the board of directors is 0.5 years and 3.3 years respectively.

Key information

David Weinstein

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownership0.2%
Management average tenureless than a year
Board average tenure3.3yrs

Recent management updates

Recent updates

CEO

David Weinstein (64 yo)

less than a year

Tenure

Mr. David H. Weinstein, also known as David, is CEO & Director of Renovaro Inc. from October 14, 2024. Mr. Weinstein has extensive experience with U.S. securities and investment banking firms. He has been...

Leadership Team

NamePositionTenureCompensationOwnership
Simon Tarsh
Interim Chief Financial Officerless than a yearUS$330.33kno data
Francois Binette
Executive VP for Research & Developmentless than a yearUS$430.29k0%
€ 0
David Weinstein
CEO & Directorless than a yearno data0.16%
€ 247.7k
Serhat Gümrükcü
Co-Founder & Inventorno datano data11.12%
€ 17.5m
Greg Duczynski
Senior Vice President for Clinical Operations2.7yrsno datano data

0.5yrs

Average Tenure

63yo

Average Age

Experienced Management: 2Q5's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
David Weinstein
CEO & Directorless than a yearno data0.16%
€ 247.7k
James McNulty
Independent Directorless than a yearno datano data
Richard Whitley
Member of Respiratory Diseases Scientific Advisory Board3.3yrsno datano data
Anna Lok
Member of HBV Scientific Advisory Board3.3yrsno datano data
Carol Brosgart
Chairperson of HBV Cure Scientific Advisory Board4.4yrsUS$129.74k0%
€ 0
Fabien Zoulim
Member of HBV Scientific Advisory Board4.4yrsno datano data
Maurice Van Tilburg
Independent Directorless than a yearno datano data
Mark Collins
Independent Directorless than a yearno datano data
W. Hardy
Chairman of HIV Scientific Advisory Board6.4yrsno datano data
Steven Deeks
Member of HIV Scientific Advisory Board6.9yrsno datano data
Peter Revill
Member of HBV Scientific Advisory Board4.4yrsno datano data
Geert Kazemier
Chairman of Scientific Advisory Boardless than a yearno datano data

3.3yrs

Average Tenure

72yo

Average Age

Experienced Board: 2Q5's board of directors are considered experienced (3.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 19:52
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Renovaro Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution